OA13365A - Substituted quinoline compounds. - Google Patents

Substituted quinoline compounds. Download PDF

Info

Publication number
OA13365A
OA13365A OA1200600247A OA1200600247A OA13365A OA 13365 A OA13365 A OA 13365A OA 1200600247 A OA1200600247 A OA 1200600247A OA 1200600247 A OA1200600247 A OA 1200600247A OA 13365 A OA13365 A OA 13365A
Authority
OA
OAPI
Prior art keywords
alkyl
group
phenyl
halo
compound
Prior art date
Application number
OA1200600247A
Other languages
English (en)
Inventor
Peter Bertinato
Michel Andre Couturier
Marcus Douglas Ewing
Ernest Seiichi Hamanaka
Ralph Pelton Robinson Jr
Derek Lawrence Tickner
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of OA13365A publication Critical patent/OA13365A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
OA1200600247A 2004-02-04 2005-01-24 Substituted quinoline compounds. OA13365A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54167804P 2004-02-04 2004-02-04
US63376304P 2004-12-06 2004-12-06

Publications (1)

Publication Number Publication Date
OA13365A true OA13365A (en) 2007-04-13

Family

ID=34890449

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200600247A OA13365A (en) 2004-02-04 2005-01-24 Substituted quinoline compounds.

Country Status (25)

Country Link
US (3) US7468378B2 (fr)
EP (1) EP1716137A1 (fr)
JP (1) JP2007520543A (fr)
KR (1) KR100799802B1 (fr)
AP (1) AP2006003685A0 (fr)
AR (1) AR047529A1 (fr)
AU (1) AU2005214159A1 (fr)
BR (1) BRPI0507462A (fr)
CA (1) CA2555133A1 (fr)
CO (1) CO5700721A2 (fr)
CR (1) CR8544A (fr)
EA (1) EA010369B1 (fr)
EC (1) ECSP066717A (fr)
GE (1) GEP20084360B (fr)
IL (2) IL176715A0 (fr)
MA (1) MA28347A1 (fr)
NL (1) NL1028192C2 (fr)
NO (1) NO20063928L (fr)
OA (1) OA13365A (fr)
PA (1) PA8623001A1 (fr)
PE (1) PE20050773A1 (fr)
SV (1) SV2007002007A (fr)
TW (2) TW200906800A (fr)
UY (1) UY28734A1 (fr)
WO (1) WO2005080373A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2544678C (fr) 2003-11-05 2013-12-31 Sunesis Pharmaceuticals, Inc. Modulateurs de l'adhesion cellulaire
AP2006003685A0 (en) * 2004-02-04 2006-08-31 Pfizer Prod Inc Substituted quinoline compounds
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
JP2007532638A (ja) * 2004-04-14 2007-11-15 アストラゼネカ・アクチエボラーグ Ｎｋ１アンタゴニスト及びセロトニン再取り込み阻害剤としてのアリールグリシンアミド誘導体及びその使用
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
BRPI0607555A2 (pt) * 2005-04-19 2009-09-15 Surface Logix Inc inibidores da proteìna microssomal de transferência de triglicirideo e secreção de apo-b
ATE520651T1 (de) * 2006-10-23 2011-09-15 Pfizer Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
CN101583593A (zh) 2006-11-13 2009-11-18 辉瑞产品公司 二芳基、二吡啶基和芳基-吡啶基衍生物及其用途
EP2115368A1 (fr) * 2007-02-02 2009-11-11 Steve D. Shivvers Dispositif de séchage à haut rendement équipé de zones de chauffage et de séchage à plusieurs étages
US20080249130A1 (en) * 2007-02-09 2008-10-09 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
WO2009014674A1 (fr) * 2007-07-23 2009-01-29 Sirtris Pharmaceuticals, Inc. Hétérocyclylamides comme inhibiteurs de la protéine de transport de triglycérides microsomal de l'intestin
CA2702577A1 (fr) 2007-10-15 2009-04-23 Jbs United, Inc. Procede permettant d'accroitre la performance d'une progeniture
ES2830024T3 (es) * 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
WO2010018547A1 (fr) * 2008-08-13 2010-02-18 Pfizer Inc. Composés aminoquinoline
EP2723718A1 (fr) 2011-06-24 2014-04-30 Amgen Inc. Antagonistes de trpm8 et leur utilisation dans le cadre thérapeutique
JP2014527511A (ja) 2011-06-24 2014-10-16 アムジエン・インコーポレーテツド Ｔｒｐｍ８拮抗剤及び治療におけるそれらの使用
US9187462B2 (en) * 2011-08-04 2015-11-17 Array Biopharma Inc. Substituted quinazolines as serine/threonine kinase inhibitors
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
US9624172B2 (en) 2014-02-17 2017-04-18 Hetero Research Foundation Polymorphs of lomitapide and its salts
TWI735416B (zh) 2014-10-06 2021-08-11 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
WO2016055934A1 (fr) * 2014-10-09 2016-04-14 Glenmark Pharmaceuticals Limited Forme amorphe du mésylate de lomitapide
ES2946970T3 (es) 2016-03-31 2023-07-28 Vertex Pharma Regulador de conductancia transmembrana de moduladores de fibrosis quística
SI3519401T1 (sl) 2016-09-30 2022-01-31 Vertex Pharmaceuticals Incorporated Modulator regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in proces za izdelavo modulatorja
CN110267948B (zh) 2016-12-09 2023-12-08 弗特克斯药品有限公司 囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
EP3640242B1 (fr) * 2017-06-16 2023-04-19 Hitgen Ltd. Composé inhibiteur de rock et utilisations correspondantes
MA49631A (fr) 2017-07-17 2020-05-27 Vertex Pharma Méthodes de traitement de la fibrose kystique
TWI799435B (zh) 2017-08-02 2023-04-21 美商維泰克斯製藥公司 製備化合物之製程
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
KR102716244B1 (ko) 2017-12-08 2024-10-14 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
EP3774825A1 (fr) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2819039A1 (de) 1978-04-29 1979-11-08 Bayer Ag Leimungsmittel fuer papier
AT377974B (de) 1981-03-11 1985-05-28 Wellcome Found Verfahren zur herstellung von neuen aromatischen carbonsaeuren und ihren salzen
WO1992018106A1 (fr) 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
HU218419B (hu) 1992-03-06 2000-08-28 E.R. Squibb And Sons, Inc. Mikroszomális triglicerid transzfer protein (MTP) nagy molekulatömegű alegységének rekombináns úton történő előállítására és a protein és inhibitorainak kimutatására szolgáló eljárások
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
SK282721B6 (sk) 1994-05-27 2002-11-06 Smithkline Beecham S.P.A. Nepeptidové NK3 antagonistické látky, spôsob ich výroby, farmaceutické prostriedky s ich obsahom a ich použitie
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
DE19519245C2 (de) * 1995-04-14 2003-04-30 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DK0832069T3 (da) 1995-06-07 2003-04-22 Pfizer Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B)
WO1996040640A1 (fr) 1995-06-07 1996-12-19 Pfizer Inc. DERIVES DE BIPHENYL-2-ACIDE CARBOXYLIQUE-TETRAHYDRO-ISOQUINOLEINE-6-YL AMIDES, PREPARATION DE CES AMIDES ET UTILISATION EN TANT QU'INHIBITEURS DE LA PROTEINE DE TRANSFERT DE TRIGLYCERIDE MICROSOMAL ET/OU DE LA SECRETION D'APOLIPOPROTEINES B (Apo B)
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
CZ296163B6 (cs) * 1996-05-20 2006-01-11 Karboxyamidy chinolinu jako inhibitory TNF a inhibitory PDE-IV
CA2259431A1 (fr) 1996-07-01 1998-01-08 Eli Lilly And Company Composes hypoglycemiques et hypolipidemiques
KR100217618B1 (ko) * 1996-12-12 1999-09-01 정몽규 와셔액 분사위치 조절 장치
AU5513298A (en) 1996-12-20 1998-07-17 Bristol-Myers Squibb Company Heterocyclic inhibitors of microsomal triglyceride transfer protein and method
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US5968950A (en) 1997-06-23 1999-10-19 Pfizer Inc Apo B-secretion/MTP inhibitor hydrochloride salt
ES2287971T3 (es) 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
AP1201A (en) 1997-09-17 2003-09-01 Smithkline Beecham Corp Method for the synthesis of quinoline derivatives.
PL341364A1 (en) * 1997-12-22 2001-04-09 Upjohn Co 4-hydroxyqinoline-3-carboxamides and hydrazides as antiviral agents
CO5090829A1 (es) 1998-07-21 2001-10-30 Novartis Ag Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b.
IL139449A0 (en) 1999-11-10 2001-11-25 Pfizer Prod Inc Use of apo b secretion/mtp inhibitors
CA2325358C (fr) * 1999-11-10 2005-08-02 Pfizer Products Inc. Amides de l'acide 7-¬(4'-trifluoromethylbiphenyl-2-carbonyl)amino|-quinoleine-3-carboxylique et methodes pour inhiber la secretion d'apolipoproteine b
US20020032238A1 (en) * 2000-07-08 2002-03-14 Henning Priepke Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
US6417367B1 (en) * 2000-08-11 2002-07-09 Pfizer Inc. Methods of making quinoline amides
CN1478077A (zh) 2000-10-05 2004-02-25 ����ҩƷ��ҵ��ʽ���� 作为apo b分泌抑制剂的苯甲酰胺化合物
KR100575944B1 (ko) 2001-06-28 2006-05-02 화이자 프로덕츠 인코포레이티드 미소체 트리글리세라이드 전달 단백질(ｍｔｐ) 및/또는아포지방단백질 ｂ(ａｐｏ ｂ)분비의 억제제로서의트리아미드-치환된 인돌, 벤조푸란 및 벤조티오펜
CN1585751A (zh) * 2001-10-25 2005-02-23 武田药品工业株式会社 喹啉化合物
WO2003049685A2 (fr) * 2001-12-07 2003-06-19 The Regents Of The University Of California Traitement de la degenerescence maculaire liee au vieillissement
US20030162788A1 (en) * 2002-01-10 2003-08-28 Boehringer Ingelheim Pharma Kg Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals
EP1479666A4 (fr) 2002-02-28 2010-10-13 Japan Tobacco Inc Compose d'esters et ses utilisation en medecine
MXPA05006744A (es) * 2002-12-20 2005-09-08 Pfizer Prod Inc Inhibidores de la proteina microsomal de transferencia de trigliceridos.
CA2510815A1 (fr) * 2002-12-20 2004-07-08 Pfizer Products Inc. Inhibiteurs de proteine de transfert de triglyceride microsomale
AP2006003685A0 (en) * 2004-02-04 2006-08-31 Pfizer Prod Inc Substituted quinoline compounds

Also Published As

Publication number Publication date
US7468378B2 (en) 2008-12-23
ECSP066717A (es) 2006-10-31
US7368573B2 (en) 2008-05-06
PA8623001A1 (es) 2006-03-24
EA200601239A1 (ru) 2007-02-27
EP1716137A1 (fr) 2006-11-02
CO5700721A2 (es) 2006-11-30
GEP20084360B (en) 2008-04-29
IL208963A0 (en) 2011-07-31
MA28347A1 (fr) 2006-12-01
US7393958B2 (en) 2008-07-01
BRPI0507462A (pt) 2007-07-10
PE20050773A1 (es) 2005-10-26
TW200906800A (en) 2009-02-16
EA010369B1 (ru) 2008-08-29
UY28734A1 (es) 2005-09-30
IL176715A0 (en) 2006-10-31
AU2005214159A1 (en) 2005-09-01
JP2007520543A (ja) 2007-07-26
WO2005080373A1 (fr) 2005-09-01
CA2555133A1 (fr) 2005-09-01
TWI306454B (en) 2009-02-21
SV2007002007A (es) 2007-03-20
US20070093525A1 (en) 2007-04-26
AP2006003685A0 (en) 2006-08-31
NL1028192A1 (nl) 2005-08-08
US20050234099A1 (en) 2005-10-20
NL1028192C2 (nl) 2006-05-30
KR100799802B1 (ko) 2008-01-31
TW200533354A (en) 2005-10-16
AR047529A1 (es) 2006-01-25
KR20060127123A (ko) 2006-12-11
CR8544A (es) 2006-11-30
US20060223851A1 (en) 2006-10-05
NO20063928L (no) 2006-10-31

Similar Documents

Publication Publication Date Title
OA13365A (en) Substituted quinoline compounds.
CN1522246B (zh) 三酰胺取代的吲哚、苯并呋喃及苯并噻吩
AP1388A (en) Nicotinamide derivatives
MXPA02009020A (es) Derivados de beta-aminoacidos ciclicos como inhibidores de las metaloproteasas de matriz y factor de necrosis de tumor alfa.
JP2001504809A (ja) マトリクス金属プロテナイーゼおよびｔａｃｅに対する阻害薬としてのオルト―スルホンアミドアリールヒドロキサム酸の製造および使用
CN107982266A (zh) 氨基甲酸酯化合物及其制备和使用方法
BRPI0809931B1 (pt) antagonistas do receptor do hormônio liberador de gonadotrofina e métodos relacionados com o mesmo
CN101180273A (zh) 合成6-烷基氨基喹啉衍生物的方法
CA2505604A1 (fr) Inhibiteurs de proteine microsomale de transfert de triglyceride
MXPA06007785A (en) Substituted quinoline compounds
JPH05239024A (ja) 縮合複素環カルボン酸誘導体、その製造法、中間体および剤
CA2799708A1 (fr) 2-phenylbenzoylamides
HK1064369B (en) Triamide-substituted indoles, benzofuranes and benzothiophenes
HK1096665B (en) Triamide-substituted indoles, benzofuranes and benzothiophenes